Navigation Links
FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry
Date:6/25/2008

d to the onset of disease. RNAi is a Nobel Prize winning technology and one of the most promising areas of drug discovery and development today.

Silence Therapeutics has developed a platform of novel short interfering RNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.

Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. Silence plans a regulatory filing in 2008 to commence clinical trials for Atu027.

In March of 2008 Silence Therapeutics announced a collaboration with AstraZeneca (LSE: AZN) focused on the development of a range of novel delivery approaches for siRNA molecules. Under the terms of the agreement both Silence Therapeutics and AstraZeneca will be allowed to commercialize the truly novel delivery systems that the two partners develop together.

In July 2007, Silence Therapeutics formed its first research and development collaboration with AstraZeneca to develop novel AtuRNAi therapeutics against five specific targets, including those in respiratory indications. This collaboration was the first industry validation of the potential application of Silence Therapeutics' proprietary AtuRNAi molecules and solidified the Company's leadership position in field of RNAi therapeutics.

The Company's AtuRNAi technology also has been sublicensed to Pfizer through Quark's license to Pfizer of the compound RTP-801i-14, for the tre
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
2. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
3. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
4. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
5. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
6. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
7. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
8. Medicare Approves in Home Sleep Apnea Testing
9. 3SBio Inc. Approves Share Repurchase Program
10. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
11. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015 DryLet, LLC ... in applications such as animal waste reduction, bioremediation, ... reduction in wastewater treatment plants and restaurant kitchen ... at the Texas Commission on Environmental Quality (TCEQ) ... Austin, Texas. , The company will highlight three ...
(Date:4/27/2015)...  Together with its customers, Elekta raised EUR 30,575 ... Barcelona . The funds will be donated ... to improve cancer care, specifically radiation oncology care, around ... patient should be denied potentially life-saving treatment simply because ... hospitals and clinics around the world to take care ...
(Date:4/24/2015)... Tempe, AZ (PRWEB) April 24, 2015 ... Arizona State University (ASU) have entered into an agreement ... , A memorandum of agreement signed by the universities ... learning, student success and other services particularly, though not ... , “We have complementary strengths and a similar set ...
(Date:4/24/2015)... , April 24, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics including high value and difficult to ... public offering of 6,000,000 shares of its common stock ... share. Of the shares being offered, 2,610,000 are being ... being offered by existing stockholders. Pfenex will not receive ...
Breaking Biology Technology:DryLet to Showcase Multiple Products at Texas Commission on Environmental Quality Trade Fair and Conference May 5-6 in Austin, Texas 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2Pfenex Inc. Announces Pricing Of Follow-on Offering 2
... into the human brain to understand its functions in ... illness — has long been a challenge for researchers. ... and sensors that can damage tissue while only reading ... Jonathan Viventi , assistant professor at ...
... Sequenom, Inc. (NASDAQ: SQNM ), a life ... it will host an Investor and Analyst Day at NASDAQ ... 2:00 to 5:00 pm ET. Key members of the company,s ... specifically focusing on the recent commercial launch of the MaterniT21 ...
... Calif., Nov. 14, 2011 VIVUS, Inc. (NASDAQ: ... TA-314, a phase 3 long-term safety and efficacy study ... erectile dysfunction (ED), was presented over the weekend at ... Meeting in Las Vegas, NV.  Andrew R. McCullough, MD, ...
Cached Biology Technology:Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures 2Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures 3Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures 4Sequenom to Host Analyst Day on Monday, November 14, 2011 215-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 215-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 315-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 4
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... When a foreign object such as a catheter enters the ... into a slick coating a biofilm that is ... cannot be defeated by a basic approach of conventional means. ... reveals the key players in the network and how they ...
... 2010 China PharmaHub Corp. (OTC Bulletin Board: ... agreement to be a distributor for Integrated Biometrics ("IB"), ...  PharmaHub will have the exclusive distribution rights in China, ... to sell IB products to customers in the Pharmaceutical, ...
... soldiers in the battlefield healthy, the U.S. Army is exploring ... Current techniques for analyzing water in the field can take ... Lipkens of Western New England College in Springfield, Massachusetts and ... They are working on an alternative technology that uses sound ...
Cached Biology News:Research provides new leads in the case against drug-resistant biofilms 2China PharmaHub Signs Distribution Agreement with Integrated Biometrics 2China PharmaHub Signs Distribution Agreement with Integrated Biometrics 3
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
R26.4C...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Anti-Mouse Macrophages (Metallophillic), Purified (Clone MOMA-1) (rat IgG2a)...
Biology Products: